A Bayesian approach for event predictions in clinical trials with time-to-event outcomes

被引:1
作者
Aubel, Paul [1 ]
Antigny, Marine [1 ]
Fougeray, Ronan [1 ]
Dubois, Frederic [1 ]
Saint-Hilary, Gaelle [1 ,2 ]
机构
[1] Inst Rech Int Servier, F-92150 Suresnes, France
[2] Politecn Torino, Turin, Italy
关键词
Bayesian; decision-making; event predictions; time-to-event; TRIFLURIDINE/TIPIRACIL PLUS BEVACIZUMAB; RECRUITMENT; ENROLLMENT; COUNTS;
D O I
10.1002/sim.9186
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In clinical trials with time-to-event outcome as the primary endpoint, the end of study date is often based on the number of observed events, which drives the statistical power and the sample size calculation. It is of great value for study sponsors to have a good understanding of the recruitment process and the event milestones to manage the logistical tasks, which require a considerable amount of resources. The objective of the proposed statistical approach is to predict, as accurately as possible, the timing of an analysis planned once a target number of events is collected. The method takes into account the enrollment, the time to event, and the time to censor processes, using Weibull models in a Bayesian framework. We also consider a possible delay in the event reporting by the investigators, and covariates may also be included. Several metrics can be obtained, such as the probability of study completion at specific timepoints or the credible interval of the date of study completion. The approach was applied to oncology trials, with progression-free survival as primary outcome. A retrospective analysis shows the accuracy of the approach on these examples, as well as the benefit of updating the predictive probability of study completion as data are accumulating or new information becomes available. We also evaluated the performances of the proposed method in a comprehensive simulation study.
引用
收藏
页码:6344 / 6359
页数:16
相关论文
共 28 条
[1]   First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design [J].
Andre, Thierry ;
Saunders, Mark ;
Kanehisa, Akira ;
Gandossi, Eric ;
Fougeray, Ronan ;
Amellal, Nadia Causse ;
Falcone, Alfredo .
FUTURE ONCOLOGY, 2020, 16 (04) :21-29
[2]  
Anisimov V., 2005, 200501 GSK BDS TR
[3]   Modelling, prediction and adaptive adjustment of recruitment in multicentre trials [J].
Anisimov, Vladimir V. ;
Fedorov, Valerii V. .
STATISTICS IN MEDICINE, 2007, 26 (27) :4958-4975
[4]   Predictive Hierarchic Modeling of Operational Characteristics in Clinical Trials [J].
Anisimov, Vladimir V. .
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2016, 45 (05) :1477-1488
[5]   Discussion on the paper "Real-Time Prediction of Clinical Trial Enrollment and Event Counts: A Review", by DF Heitjan, Z Ge, and GS Ying [J].
Anisimov, Vladimir V. .
CONTEMPORARY CLINICAL TRIALS, 2016, 46 :7-10
[6]   Predictive event modelling in multicenter clinical trials with waiting time to response [J].
Anisimov, Vladimir V. .
PHARMACEUTICAL STATISTICS, 2011, 10 (06) :517-522
[7]   Statistical Modeling of Clinical Trials (Recruitment and Randomization) [J].
Anisimov, Vladimir V. .
COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 2011, 40 (19-20) :3684-3699
[8]   Predicting analysis times in randomized clinical trials [J].
Bagiella, E ;
Heitjan, DF .
STATISTICS IN MEDICINE, 2001, 20 (14) :2055-2063
[9]   A systematic review of models to predict recruitment to multicentre clinical trials [J].
Barnard, Katharine D. ;
Dent, Louise ;
Cook, Andrew .
BMC MEDICAL RESEARCH METHODOLOGY, 2010, 10
[10]   Practical considerations for estimating clinical trial accrual periods: Application to a multi-center effectiveness study [J].
Carter R.E. ;
Sonne S.C. ;
Brady K.T. .
BMC Medical Research Methodology, 5 (1)